SCHEMBL4471424

SCHEMBL4471424

COc1cc2c(Oc3ccc(NC(=O)NCCC(C)(C)C)cc3Cl)ccnc2cc1OCCCN1CCC(CCO)CC1

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.54
FLT3 P36888 4/20 0.52
PDGFRA P16234 2/20 0.52
KIT P10721 1/20 0.52
KDR P35968 1/20 0.52
MST1R Q04912 1/20 0.52
FGFR2 P21802 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4475416 0.97 FGFR2 (0.54) METFLT3PDGFRAKITKDR
SCHEMBL4474813 0.95 FGFR2 (0.56) METFLT3PDGFRAKITKDR
SCHEMBL4471703 0.93 MET (0.56) METFLT3PDGFRAKITKDR
SCHEMBL4473920 0.92 MET (0.61) METFLT3PDGFRAKITKDR
SCHEMBL4476312 0.92 FGFR2 (0.60) METFLT3PDGFRAKITKDR
SCHEMBL4471915 0.91 PDGFRA (0.63) METPDGFRAKITKDRFGFR2
SCHEMBL4470936 0.91 PDGFRA (0.63) METPDGFRAKITKDRFGFR2
SCHEMBL4478109 0.91 MET (0.59) METFLT3KITKDRMST1R
SCHEMBL4475392 0.89 MET (0.52) METFLT3PDGFRAKITKDR
SCHEMBL4486831 0.89 FLT3 (0.64) METFLT3PDGFRAKITKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 MET 6/4885FLT3 27/4885PDGFRA 372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.